cyrilzakka/clinical-trials huggingface dataset:
Instrument-Assisted Soft Tissue Mobilization on Gastrocnemius and Achilles Tendon in Plantar Fasciitis

Aim of this study is to compare the effects of instrument assisted soft tissue mobilization on gastrocnemius and Achilles tendon on pain,range of motion and foot disability.A randomized control trial that will include total 32 participants and divided into two groups.Patients in Group A will receive instrument assisted soft tissue mobilization of gastrocnemius and Group B will receive instrument assisted soft tissue mobilization of Achilles tendon. While conventional therapy will be given to both groups.Data collected will be analyzed through SPSS 25.

Plantar fasciitis is typical condition that produces pain in the medial longitudinal arch of the foot.Repetitive traction stresses on the plantar fascia at its origin over the distal calcaneus obesity, the makeup of the feet, and lifestyle choices are all factors that might contribute to the development of PF.

Physiotherapy interventions includes stretching the gastrocnemius and soleus,dry needling, IASTM (instrument assisted soft tissue mobilisation), exercise therapy, ultrasound therapy, iontophoresis, laser therapy, splints, and taping.Use of Instrument-Assisted Soft Tissue Massage has increased in popularity, and the plantar fascia is a superficial tissue that may benefit from this treatment.The Graston Technique Instrument-assisted Soft Tissue Mobilisation not only increases blood flow and tissue healing to the area as well as breaking up soft tissue restrictions along with increase fibroblasts, mast cell production and phagocytes.

Previous literature were limited in sample size, and only immediate effects of these techniques were studied But this study opted for the long term use of graston technique on gastrocnemius in comparison on Achilles tendon. So the purpose of this study is to compare the effects of Graston technique instrument assisted soft tissue mobilization at gastrocnemius and Achilles tendon in patients with planter fascitis. It will add to the growing body of knowledge that if same technique on different soft tissues will yield comparable outcomes,which should be the alternate choice of therapy

Eligibility Criteria:
Inclusion Criteria:

* Both male and female
* Participants between age of 25 and 50 years
* Patients with maximal pain located at the antero-medial aspect of the plantar surface of the calcaneus
* Pain aggravated by passive dorsiflexion or standing/ walking on the big toe
* Patients with pain on taking first step in the morning(18)
* Patient volunteer to participate in the study and signed informed consent.

Exclusion Criteria:

* Patient with history of musculoskeletal disorders.
* Patient with any previous history of ankle or foot surgery.
* Patient with history of ankle or foot fracture.
* Patient with severe bone disorder (osteoporosis)
* Patient with history of Venous insufficiency.
Pancreatic Cancer Molecular Sub-classification Using Endoscopic Ultrasound Tissue Core Biopsy Samples

This study evaluated the feasibility and reliability of PDAC molecular subtyping on tissue core biopsies samples acquired under EUS guidance. Moreover, this study will assess the impact of molecular subtypes assessed on EUS-FNB samples in patients with resectable and unresectable (locally advanced, advanced, and metastatic) PDAC undergoing chemotherapy on treatment response and survival and the utility in monitoring disease response to therapy and early occurrence of disease relapse using the TaqMan RNA assay in serum

PDAC patients are categorised as resectable, borderline resectable, locally advanced, metastatic and recurrent. Substantial neoplastic tissue is only available for the resectable group. This is unfortunate as the other groups are those that would benefit the most from molecular characterization and identification of markers, which may be predictive and/or provide therapeutic stratification. For these categories of patients, only fine needle aspiration or small biopsies could be obtained until now. However, the introduction of new needles, specifically designed to acquire larger high quality biopsy samples under endoscopic ultrasound (EUS), has now made it possible to test prognostic, predictive and therapeutic stratification markers. However, the applicability of EUS-fine needle biopsy (EUS-FNB) samples for this purpose has yet to be clinically validated. The working hypothesis of this proposal is that the molecular sub-classification of PDAC on EUS-FNB tissue samples could be applied for prognostic stratification and therapeutic decision strategies in both resectable and unresectable patients using DNA and RNA biomarkers.

Eligibility Criteria:
Inclusion Criteria:

* Patients referred to EUS with FNB in the suspect of pancreatic cancer
* Availability of biopsies obtained during EUS-FNB
* Histological diagnosis of pancreatic ductal adenocarcinoma of any stage
* Age \>18 and \<80 years
* Willing to be followed up at the Fondazione Policlinico A. Gemelli University Hospital
* Able to sign informed consent

Exclusion Criteria:

* Histological diagnoses other than pancreatic ductal adenocarcinoma
* Pregnancy or lactation
* Unable to sigh informed consent
Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

The purpose of this survey is to evaluate the safety and effectiveness of long-term administration of vonoprazan tablets when used as maintenance therapy for reflux esophagitis in routine clinical settings.

The drug being tested in this survey is called vonoprazan. Vonoprazan is being tested to treat patients who have reflux esophagitis.

This survey will look at the safety and effectiveness of long-term administration of vonoprazan tablets when used as maintenance therapy for reflux esophagitis in routine clinical settings. The survey will enroll approximately 1000 participants.

- Vonoprazan 10 mg or 20 mg

This multi-center observational trial will be conducted in Japan.

Eligibility Criteria:
Inclusion Criteria:

- Participants who require maintenance therapy for relapsed/recurrent reflux esophagitis

Exclusion Criteria:

* Participants meeting the criteria of grade A to D according to the Los Angeles classification (Hoshihara's modification), by means of endoscopy at the initiation of maintenance therapy with vonoprazan tablets
* Participants with a previous history of hypersensitivity to ingredients in vonoprazan tablets
* Participants taking atazanavir sulfate or rilpivirine hydrochloride
Omega-3 and Cardiovascular Risk Factors and Kidney Related Biomarkers

In this study, 99 overweight or obese women that referred to the Clinic Nutrition to lose weight were randomly divided into three groups according to body mass index (BMI) by random-number table (figure1). We attempted to match all three groups for BMI, probable medications, and age. Subjects were excluded if they had risk factors of cardiovascular diseases or allergic reactions to fish or walnut, or received lowering blood glucose or lipid profile agents. Also, participants with weak economic status could not enter to this study (due to the high cost of fish and walnuts). Before the start of this study, the information in the form of questionnaire about demographic, medical history, and medication use, was completed. Participants were aware about overview of this study, and completed the consent form. The NATIONAL INSTITUTED FOR MEDICAL RESEARCH DEVELOPMENT (NIMAD), approved all procedures involving human subjects. The study has been done in accordance with the ethical standards in declaration of Helsinki.

Then all of the three groups received a low-calorie diet in order to lose weight. The distribution of macronutrients was similar in three groups (carbohydrate 55%, fat 33%, and protein 17%). The amount of different fatty acids (saturated, unsaturated with mono double bond, and polyunsaturated fatty acids) intake in these diets was the same but the sources of omega-3 between these groups were different. In the first group, subjects were instructed to consume 300 gram fatty fish, such as Salmon fish during a week in two separated meals (each meal 150 gr fatty fish) and to avoid consumption of plant sources of omega-3 (soybean oil, canola, flaxseed and walnuts). In the second group, subjects were asked to consume walnuts three times a week and each time two walnuts (totally 18 walnuts/wk) and avoid the consumption of fish. And in the third group, subjects were recommended to consume 150 g fatty fish during a week and nine walnuts. The amount of omega-3 fatty acids considered in this study covered the typical recommended intake (0.3 to 0.5 g/d of EPA+DHA and 0.8 to 1.1 g/d of ALA)(14). Dietary intakes of all patients were controlled by a dietitian and they were followed for 12 weeks. Dietary intakes were assessed by three dietary records (one weekend and two week days).

This is a clinical trial which conducted on over weight and obese female.

Eligibility Criteria:
Inclusion Criteria:

* over weight or obese

Exclusion Criteria:

* have any diseases
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma


Eligibility Criteria:
Inclusion Criteria:

* Advanced unresectable hepatocellular carcinoma confirmed by histology or cytology
* Age 20-79
* At least one measurable lesion defined in RECIST version 1.1
* Child Pugh grade B
* ECOG PS score 2
* The expected life is at least 90 days

Exclusion Criteria:

* Previously received anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibody treatment, or any other treatment that regulates T cells
* Received systemic corticosteroid or immunosuppressive therapy within 28 days before enrollment
* Complicated with autoimmune diseases or having a history of chronic or recurrent autoimmune diseases
* History of pleural or pericardial adhesions within 28 days before enrollment
* HIV antibody, HTV-Ⅰantibody, HCV antibody, hepatitis B surface protein antigen, hepatitis B surface protein antibody, hepatitis B core protein antibody or any detectable hepatitis B virus DNA test results were positive
* Multiple primary cancers (excluding completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, and any other cancer that has not recurred for at least 5 years)
* Brain or meningeal metastasis (unless asymptomatic and does not require treatment)
* Uncontrollable or serious cardiovascular disease.
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria
* Body surface area affected by atopic dermatitis at or less than 15% at start of treatment

Exclusion Criteria:

* Pregnancy and breast-feeding
* Conditions that may pose a threat to the patient or effect the outcome of the study
* Wide-spread atopic dermatitis (AD) requiring systemic treatment
* Immuno-compromized conditions
* At least 2 weeks after local AD treatment and treatment with systemic antibiotics
* At least 1 month after systemic AD treatment
Prognostic Value of Biochemical Markers in Cerebrospinal Fluid for Functional Outcome of Spinal Cord Injured Patients

The project is aimed to develop predictive indices of spinal cord injury severity through the analysis of cerebrospinal fluid of patient collected during acute injury.


Eligibility Criteria:
Inclusion Criteria:

* presence of cervical and thoracic Spinal Cord Injury
* need to be submitted to spine surgical stabilization with posterior approach

Exclusion Criteria:

* prior to recruitment, in the acute phase, treatment with steroid therapy
Post-resuscitation Care Registry for Survival From Out-of-hospital Cardiac Arrest

The aim of this study is to construct multi-center post-cardiac arrest care registry that can be used for data warehousing and clinical research.

This registry prospectively enrolls adults patients survived out-of-hospital cardiac arrest in 3 academic hospital emergency departments.

Registered data can be used for quality control and clinical research to reduce post-cardiac arrest syndrome-related mortality.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 20 years old or older who presents to the ED of the participating hospitals with any of the following criteria:

  1. Sustained ROSC from OHCA at pre-hospital level
  2. Sustained ROSC from OHCA at the ED of the participating hospitals after ACLS
  3. Patients sustained ROSC from OHCA and transferred from other hospital to the ED of the participating hospitals for post-cardiac arrest care

Exclusion Criteria:

* Age less than 20 years old
* Patients with advanced directives not to deliver aggressive organ supportive management
Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy

The purpose of this study is to determine the role of endoscopic ultrasound measurement of the primary tumor maximum diameter changes in absolute / relative values in predicting the tumor regression after concurrent chemoradiotherapy for rectal cancer.

We use endoscopic ultrasound to measure the primary tumor maximum diameter changes to predict the tumor regression after concurrent chemoradiotherapy for rectal cancer

Eligibility Criteria:
Inclusion Criteria:

* pathologically confirmed rectal cancer, preoperative stage II / III (T3-4N0 or T1-4N + M0).
* tumor distance from anus less than 12 cm.
* KPS score not less than 70
* can be tolerated chemotherapy and radiotherapy.
* pelvic who had no history of radiation therapy.
* Non-allergic history of fluorouracil or platinum-based chemotherapy drugs.
* a full understanding of the study, the ability to complete all of the treatment plan, follow up the conditions and sign the informed consent.

Exclusion Criteria:

* other malignancy (past or at the same time), does not include curable non-melanoma skin cancer and cervical carcinoma in situ; does not include resectable primary colon cancer (synchronous or metachronous).
* pregnant or lactating patients.
* fertility but did not use contraceptive measures.
* existing active infection.
* merge serious complications, can not tolerate the treatment, such as 6 months of myocardial infarction, mental illness, uncontrollable diabetes or uncontrollable hypertension or hypotension.
* concurrent treatment with other anticancer drugs.
* can not complete treatment or follow-up.
PartoSure to Predict Spontaneous Preterm Delivery in Pregnancies After Assisted Reproductive Technology (ART)

To calculate sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) of PartoSure TTD test in predicting delivery within 7 or 14 days from testing and to compare it with cervical length (CL) measurement by transvaginal ultrasound (15 mm cut-off)

* This trial is a prospective observational study.
* Pregnancies after ART between 20 0/7 and 36 6/7 weeks with symptoms of preterm labor, clinically intact membranes, cervical dilatation of ≤ 2 cm will be invited to participate to the study. Signed consent form is required to be able to participate to the study.
* PartoSure and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
* Trial Population:Pregnancies after ART between 20 0/7 and 36 6/7 weeks with symptoms of preterm labor are hospitalized at My Duc hospital from October 2015 to April 2016. The sample size for this trial of 100 subjects.

Eligibility Criteria:
Inclusion Criteria:

To be eligible for enrollment into this trial, each female subject must fulfill all of the following criteria at the start of enrollment:

* Pregnancies after assisted reproductive technology include singleton and twins
* Between 20 0/7 and 36 6/7 weeks with symptoms of preterm labor including uterine contractions, intermittent lower abdominal pain and pelvic pressure.
* Clinically intact membranes.
* Cervical dilatation of ≤ 2 cm
* Agree to participate in the study, and to disclose any medical events to the investigator
* Have given written informed consent

Exclusion Criteria:

To be eligible for enrollment in this study each subject must not meet any of the following criteria:

* Vaginal bleeding
* Overt rupture of the fetal membranes as indicated by visualized leakage of fluid from the cervix
* Placenta previa
* Cervical cerclage in place
* Received tocolytic medications for treatment of threatened preterm delivery prior to collection of the cervicovaginal specimens or CL measurement.
* Digital exam prior to specimen collection.
* A symptom not associated with idiopathic threatened preterm delivery (e.g trauma)
* Enrollment in a tocolytic study.
Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method

The purpose of this study is to evaluate the safety, efficacy, and tolerability of treatment with the Liposonix System (Model 2)using a single pass technique.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, 18 to 65 years of age
* Body Mass Index of ≤30 kg/m2
* Thickness of subcutaneous adipose tissue in the anticipated treatment area of ≥ 2.3 cm
* Subjects must agree to not alter their normal and regular diet or exercise routines during the course of the study
* Subject must understand the nature of the study and sign an IRB approved Informed Consent

Exclusion Criteria:

* Subject is pregnant
* Subject is diagnosed with coagulation disorders or are receiving anticoagulant therapy or medications or dietary supplements which impede coagulation or platelet aggregation
* Subject has diabetes or cardiovascular disease
* Subject has had prior aesthetic procedures to the region to be treated
* Subject has had previous open or laparoscopic surgery in the anticipated treatment area
* Subject is on prescription or over the counter weight reduction medication or programs, or had weight reduction procedures
* Subjects undergoing chronic steroid or immunosuppressive therapy
* Subject has cardiac pacemakers or any implantable electrical device
* Subject has a History of cancer
* Subject has sensory loss or dysesthesia in the area to be treated
* Subjects who are unable, or lack the capacity, to self consent
Evaluation of Integrated Optimization Schemes for Female Stress Incontinence

The aim of this study is to determine the effectiveness of PFMT added to EA vs PFMT added sham EA for SUI in women.

We will perform a multicenter, randomized, double-blind, sham-controlled, parallel-group clinical trial in four hospitals in China to compare the effectiveness of EA added to PFMT vs sham EA added to PFMT for women with SUI.

The participated women with SUI will be recruited from four participating hospitals or through community clinics by advertising. Participated hospitals include: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine (Shanghai, China); Shaanxi Hospital of Traditional Chinese Medicine (Xi'an, China); First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (Tianjin, China); and Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine (Nanjing, China).

Patients will be screened for eligibility. Chief complaint, medical history, and general characteristics (such as age, race, education level, body mass index, manner of child delivery, menopause) will be obtained. Those who met inclusion criteria and are interested in participating in the study will sign an informed consent form and then make another appointment to complete the baseline data collection, including the 72-hr bladder diary, 1-h pad test, International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) score, the weekly mean number of urine pads used). Participants will then be assigned randomly to either a PFMT (3 sets/day for 8 weeks) + EA (3 times per week for 8 weeks) group or a PFMT + sham EA group. The primary and secondary outcome will be measured from week 2 to 32. The participant-reported severity of UI and subjective self-evaluation of therapeutic effects will be recorded. Written informed consent will be obtained from all participants before they are included in the study. All clinical investigations will be conducted according to the principles of the Declaration of Helsinki.

Eligibility Criteria:
Inclusion Criteria:

* Women who are 40-75 years of age
* Involuntary leakage of urine during increased intra-abdominal pressure in the absence of a bladder contraction, such as coughing, sneezing, or other physical activities
* a 1-hour pad test exceeds 1 g
* no other treatments are administered for urinary incontinence currently

Exclusion Criteria:

* Subject has urgency and mixed urinary
* Subjects with pelvic organ prolapse, pregnancy, a history of pelvic surgery, chronic respiratory diseases, urinary tract infection, cardiac pacemaker installation, metal allergy, severe needle fear, and currently taking medications for SUI or psychological disorders.
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.


Eligibility Criteria:
Inclusion Criteria:

* Subjects voluntarily sign the informed consent form (ICF);
* Age ≥ 18 years, either male or female;
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
* Expected life expectancy is greater than 24 weeks;
* Diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) according to World Health Organization (WHO)；
* The patients understands the purpose of and procedures required for the study and is willing to participate in the study；

Exclusion Criteria:

* Subjects with congestive heart failure, uncontrolled or unstable angina or myocardial infarction,cerebrovascular accident, or pulmonary embolism within 6 months prior to screening;
* Subjects suffering from arrhythmia and requiring treatment, or QTcB \> 480ms at screening;
* Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal infections requiring treatment at screening;
* Subjects with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC);
* Female subjects who are pregnant, currently breastfeeding, planning to become pregnant;
* Subjects who had experienced malignant tumors (except for adequately treated local basal cell or squamous cell carcinoma of the skin and cervical carcinoma in situ that have been cured) within the past 5 years;
* Subjects who have any other conditions that are not specified in the protocol but the investigator believes that they are not suitable for inclusion in this trial.